Corvus Pharmaceuticals publishes Phase 1 soquelitinib data in Blood
Corvus Pharmaceuticals has announced the peer-reviewed publication of final Phase 1/1b clinical data for soquelitinib in the journal Blood, providing the first comprehensive account of the oral ITK inhibitor's performance in patients with advanced T cell lymphoma.
The South San Francisco-based company enrolled 75 heavily pre-treated patients across multiple T cell lymphoma subtypes, including peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma and adult T cell lymphoma/leukemia. The median number of prior therapies was three, and only 31% of participants had achieved an objective response to their most recent treatment, underlining the severity of the population studied.
Clinical results
The selected therapeutic dose of 200 mg twice daily was chosen on the basis of biomarker studies confirming complete ITK target occupancy at that level and above. Within the 200 mg cohort, Corvus focused its efficacy analysis on the 24 patients who had received one to three prior lines of therapy, judging them the most likely to respond. That subgroup achieved objective responses in nine of 24 patients, comprising six complete and three partial responses. Median progression-free survival reached 6.2 months, with 30% of patients remaining progression-free at 18 months. Median overall survival was 28.1 months, with 67% of patients alive at 24 months.
The tolerability profile was notable: soquelitinib produced no dose-limiting toxicities across all cohorts up to 600 mg twice daily, and the company reported no myelosuppression or immunosuppression, side effects that commonly limit other agents used in haematological malignancies.
Richard Miller, co-founder, president and chief executive of Corvus, said the data "compare favourably to currently available therapies" and underpin the rationale for the ongoing Phase 3 programme. The publication also characterises soquelitinib's mechanism in detail, including RNA sequencing data from paired tumour biopsies showing increased intratumoral Th1 cells by day eight of treatment, an effect the company interprets as direct evidence linking the drug's immunobiology to its clinical activity.
Regulatory and competitive context
The regulatory backdrop for soquelitinib in PTCL is notable. The FDA has granted the compound both Orphan Drug Designation for T cell lymphoma and Fast Track designation for relapsed/refractory PTCL. Crucially, no agent has yet achieved full FDA approval in the relapsed/refractory PTCL setting on the basis of a randomised controlled trial; existing options such as belinostat and pralatrexate carry accelerated approvals, and both are the active comparators in Corvus's 150-patient Phase 3 study, which uses progression-free survival as its primary endpoint.
The broader ITK inhibitor space remains relatively uncrowded compared with the well-trodden BTK inhibitor class. Soquelitinib's selectivity profile and the mechanistic rationale for use across immune-inflammatory indications set up an interesting read-across: Corvus is simultaneously running a Phase 2 study in atopic dermatitis and planning trials in hidradenitis suppurativa and asthma. The Th2-skewing biology relevant to PTCL is directly applicable to these allergic and inflammatory conditions, meaning positive Phase 3 data in PTCL could meaningfully de-risk the broader platform.
For investors and clinicians, the near-term catalysts are enrolment completion in the Phase 3 PTCL trial and emerging data from the SIERRA1 Phase 2 atopic dermatitis study. The Blood publication will also widen soquelitinib's visibility among haematologists, potentially accelerating site participation and recruitment momentum.